25
Participants
Start Date
March 7, 2017
Primary Completion Date
November 7, 2019
Study Completion Date
November 7, 2019
N-Rephasin® SAL200
A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
Placebo
A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
Seoul National University Bundang Hospital, Seongnam-si
Seoul National University Hospital, Seoul
Lead Sponsor
Intron Biotechnology, Inc.
INDUSTRY